Both CTI BioPharma Corp. (NASDAQ:CTIC) and REGENXBIO Inc. (NASDAQ:RGNX) are Biotechnology companies, competing one another. We will contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CTI BioPharma Corp.	12.28M	5.20	44.51M	-0.87	0.00
REGENXBIO Inc.	218.50M	8.83	99.94M	2.26	23.51

Table 1 showcases the top-line revenue, earnings per share and valuation of CTI BioPharma Corp. and REGENXBIO Inc.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
CTI BioPharma Corp.	-362.46%	-77.4%	-49.1%
REGENXBIO Inc.	45.74%	24.6%	23.3%

Liquidity

CTI BioPharma Corp.’s Current Ratio and Quick Ratio are 3.6 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor REGENXBIO Inc. are 20.2 and 20.2 respectively. REGENXBIO Inc. therefore has a better chance of paying off short and long-term obligations compared to CTI BioPharma Corp.

Insider & Institutional Ownership

Institutional investors held 62.1% of CTI BioPharma Corp. shares and 81.5% of REGENXBIO Inc. shares. 0.1% are CTI BioPharma Corp.’s share held by insiders. On the other hand, insiders held about 1.2% of REGENXBIO Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CTI BioPharma Corp.	-11.9%	-14.45%	-23.32%	-69.86%	-43.94%	-44.78%
REGENXBIO Inc.	-11.15%	-27.87%	-26.48%	-6.78%	75.68%	60.09%

For the past year CTI BioPharma Corp. had bearish trend while REGENXBIO Inc. had bullish trend.

Summary

REGENXBIO Inc. beats on 11 of the 11 factors CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV vectors to various other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.